BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 7646540)

  • 1. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.
    Izbicka E; Diaz A; Streeper R; Wick M; Campos D; Steffen R; Saunders M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):993-9. PubMed ID: 19221750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex.
    Orlandi L; Bearzatto A; Abolafio G; De Marco C; Daidone MG; Zaffaroni N
    Br J Cancer; 1999 Sep; 81(2):252-60. PubMed ID: 10496350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
    Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
    Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
    Aherne GW; Hardcastle A; Raynaud F; Jackman AL
    Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
    Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
    Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular, biochemical, and cellular pharmacology of pemetrexed.
    Goldman ID; Zhao R
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
    Takemura Y; Jackman AL
    Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
    Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.